The content on this site is intended for healthcare professionals only
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
28 Jun 2022
Cancer patient symptom and physical function reporting by caregivers used as pre...
Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, ...
21 Jun 2022
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
21 Jun 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphom...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
21 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
14 Jun 2022
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractio...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
14 Jun 2022
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
13 Jun 2022
Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive AL...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
13 Jun 2022
Subcutaneous isatuximab administration by an on-body delivery system in combinat...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
13 Jun 2022
A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy
13 Jun 2022